Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q1 2023 · 10-Q
Revenue$1.96M$1.96M+22.2% vs Q1 2022 Net Income-$475.98K-$475.98KN/M vs Q1 2022 EPS Diluted-$0.06-$0.06N/M vs Q1 2022 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flow-$1,468,214N/M Margins · derivedGross margin9.1%+19.6 pt vs Q1 2022
Operating margin-20.3%+36.6 pt vs Q1 2022
Net margin-24.3%+39.9 pt vs Q1 2022
ended Mar 31, 2023 · filed May 12, 2023 · 42 d after period end